Longeveron Inc. focuses on developing stem cell treatments for critical conditions such as Hypoplastic Left Heart Syndrome (HLHS), advancing a Phase 2b trial for its lead product Laromestrocel with ongoing dialogue with the FDA. The company’s proprietary cardiomyogenic stem cell platform underpins its niche competitive moat, but Longeveron remains a pre-commercial entity confronted by steep operating losses and negative cash flows. The recent $30 million capital raise extends its runway through late 2026, yet the business faces substantial going concern risks and dependence on further financing. Key upcoming milestones center on Phase 2b trial outcomes and regulatory feedback, while capital allocation prioritizes R&D over shareholder returns amid a negative ROE environment.